Poor
Partially Aligned
Patient Risk:
Moderate
Summary
Only the claims about visual inspection (clear/colorless, no visible particles) align with the provided FDA label excerpt. Multiple expiration/discard and expired/improperly stored efficacy claims are unsupported by the supplied label sections.
Category Scores
Accurate Statements
Lantus should be a clear solution (not cloudy or discolored).
Supported by 2.1 Important Administration Instructions: use only if the solution is clear and colorless with no visible particles.
If Lantus looks different (not clear), it should not be used.
Supported by 2.1 Important Administration Instructions: only use if the solution is clear and colorless with no visible particles.
Unsupported Statements
Lantus (insulin glargine) has an expiration date printed on the vial or pen.
Not supported by the provided label excerpts (no expiration-date/printing statement present in supplied sections).
Lantus should not be used after its expiration date.
Not supported by the provided label excerpts (no expiration/discard instruction present in supplied sections).
Using insulin after it expires can mean the medication may not work as expected.
Not supported by the provided label excerpts (no label language provided linking expiry to reduced expected effect).
Insulin products have an expiration date for unopened pens/vials (the date printed on the label).
Not supported by the provided label excerpts (no unopened/label-print expiration statement present).
Insulin products have a separate in-use period after first opening under specific storage conditions.
Not supported by the provided label excerpts (no in-use period after first opening present in supplied sections).
Expired or improperly stored insulin may provide less glucose-lowering effect.
Not supported by the provided label excerpts (no label language provided addressing glucose-lowering effect changes due to expiry/improper storage).
Expired or improperly stored insulin may raise blood sugar.
Not supported by the provided label excerpts (no label language provided addressing increased blood sugar due to expiry/improper storage).
Contradictions
Important Omissions
If the evaluation depends on expiration/discard or in-use time guidance, the provided excerpts do not include the relevant storage/how supplied/handling expiration/discard instructions needed to verify those claims.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several expiry/in-use and expired/improperly stored efficacy claims are unsupported by the provided label excerpts; if relied upon, they could misinform appropriate handling/use. The only clearly label-supported content concerns visual inspection (clear/colorless, no visible particles).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple expiration/discard and expired/improperly stored effect claims are not supported by the provided FDA label sections.
Suggested Improvement
Limit statements to label-supported administration/inspection guidance from 2.1, or provide the specific How Supplied/Storage and Handling/expiration/discard sections to accurately extract and verify expiry and in-use period claims.